Stockscreener 앱 받기
8.66
7.31%
0.59
시장 영업 전:
5.02
-3.64
-42.03%
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential - TipRanks
(DAWN) Proactive Strategies - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Rhumbline Advisers Has $957,000 Stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 5.5% on Analyst Downgrade - Defense World
JPMorgan Chase & Co. Lowers Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target to $34.00 - Defense World
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory - Insider Monkey
HC Wainwright Issues Positive Estimate for DAWN Earnings - MarketBeat
What is Wedbush's Forecast for DAWN Q1 Earnings? - MarketBeat
Research Analysts Offer Predictions for DAWN Q1 Earnings - Defense World
Needham & Company LLC Reaffirms Buy Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - MarketBeat
What is Wedbush’s Forecast for DAWN Q1 Earnings? - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Quarterly Earnings Results, Misses Estimates By $0.34 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Releases Earnings Results, Misses Expectations By $0.34 EPS - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Reaches New 1-Year Low After Earnings Miss - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $36.00 Price Target at HC Wainwright - MarketBeat
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates - MSN
Wedbush Reiterates “Outperform” Rating for Day One Biopharmaceuticals (NASDAQ:DAWN) - Defense World
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 52-Week Low Following Weak Earnings - Defense World
Day One Biopharma’s Earnings Call Highlights Growth and Challenges - TipRanks
Day One Biopharmaceuticals, Inc.'s (NASDAQ:DAWN) Profit Outlook - Simply Wall St
Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial - TipRanks
Day One Biopharmaceuticals' (DAWN) Outperform Rating Reiterated at Wedbush - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q4 2024 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Day One Biopharmaceuticals Q4 2024 results show growth - Investing.com Australia
Earnings call transcript: Day One Biopharmaceuticals Q4 2024 results show growth By Investing.com - Investing.com South Africa
Day One Biopharmaceuticals Reports Strong 2024 Results - TipRanks
Adam Dubow Sells 4,646 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock - MarketBeat
Day One Biopharmaceuticals Reports 2024 Financial Results - TipRanks
Day One Biopharmaceuticals, Inc. SEC 10-K Report - TradingView
Earnings Flash (DAWN) Day One Biopharmaceuticals Posts Q4 Revenue $131.2M, vs. FactSet Est of $27.8M - Marketscreener.com
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress - GlobeNewswire
Can Day One's 44% OJEMDA Revenue Surge Accelerate Path to Profitability? - StockTitan
Take off with Day One Biopharmaceuticals Inc (DAWN): Get ready for trading - SETE News
Day One Biopharmaceuticals (DAWN) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Day one biopharmaceuticals’ COO York sells $52,278 in stock By Investing.com - Investing.com Australia
Day one biopharmaceuticals' COO York sells $52,278 in stock By Investing.com - Investing.com South Africa
Day one biopharmaceuticals’ COO York sells $52,278 in stock - Investing.com India
Day one biopharmaceuticals general counsel sells $55,580 in stock By Investing.com - Investing.com Nigeria
Day One Biopharmaceuticals CEO sells shares for $144,130 By Investing.com - Investing.com Nigeria
Day One Biopharmaceuticals CEO sells shares for $144,130 - Investing.com
Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Monday - MarketBeat
TimesSquare Capital Management LLC Has $21.68 Million Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - MarketBeat
(DAWN) Trading Advice - Stock Traders Daily
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Day One Bio's Talks With FDA Help Secure Glioma Drug Approval - Clinical Leader
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect? - Yahoo Finance
New Strong Buy Stocks for February 13th - Yahoo Finance
The Goldman Sachs Group Issues Pessimistic Forecast for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price - MarketBeat
Day One Biopharmaceuticals to Host Conference Call to Discuss Q4 and Full-Year 2024 Financial Results and Corporate Progress - Nasdaq
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025 - GlobeNewswire
2.14%
2.83%
자본화:
|
볼륨(24시간):